coadministration การใช้

• This advance allows administration of the virus without coadministration with interferon.
• Thus, coadministration is not recommended.
• The coadministration of tenofovir and atazanavir results in decreased concentrations of atazanavir and increased concentrations of tenofovir.
• Its formation can be blocked by the coadministration of dutasteride, a potent and selective 5?-reductase inhibitor.
• Coadministration of bilastine and grapefruit juice ( a known P-glycoprotein-mediated drug transport activator ) significantly reduced bilastine systemic exposure.
• Likewise, coadministration of bilastine 20 mg and ketoconazol 400 mg does not produce any significant prolongation of the QT / QTc interval attributable to bilastine.
• A recent study reported a synergistic effect for weight loss with leptin and amylin coadministration in diet-induced obese rats by restoring hypothalamic sensitivity to leptin.
• Coadministration of moxifloxacin with other drugs that also prolong the QT interval or induce bradycardia ( e . g ., beta-blockers, amiodarone ) should be avoided.
• Patients treated with both paroxetine and tamoxifen have a 67 % increased risk of death from breast cancer, from 24 % to 91 %, depending on the duration of coadministration.
• Coadministration of statins with phytosterol-enriched foods increases the cholesterol-lowering effect of phytosterols, again without any proof of clinical benefit and with anecdotal evidence of potential adverse effects.
• Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug.
• Ritonavir is a common drug used in the treatment of HIV . Coadministration of ritonavir and fluticasone may lead to increased levels of fluticasone in the body, which may lead to Cushing s Syndrome and adrenal suppression.
• Coadministration of certain fluoroquinolones and other drugs primarily metabolized by CYP1A2 ( e . g . theophylline, methylxanthines, tizanidine ) results in increased plasma concentrations and could lead to clinically significant side effects of the coadministered drug.
• Coadministration of a protease inhibitor with a PDE5 inhibitor is expected to substantially increase the PDE5 inhibitor concentration and may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual changes, and priapism.
• In addition, coadministration of sofosbuvir with anticonvulsants ( carbamazepine, phenytoin, phenobarbital, oxcarbazepine ), antimycobacterials ( rifampin, rifabutin, rifapentine ), and the HIV protease inhibitor tipranavir and ritonavir is expected to decrease sofosbuvir concentration.
• Das et al . implicated 4-OH-E 2 in the induction of estrogen-responsive genes, a response that exhibited partial or no abrogation by coadministration with an antiestrogen, providing evidence for the ability of 4-OH-E 2 to carry out genetic upregulation via a pathway independent of ER signalling.
• The Thorough QT / QTc study was designed to assess the effect on the QT / QTc interval, both of the therapeutic dose ( 20 mg ) and 100 mg of bilastine, but also the coadministration of the therapeutic dose with usual doses of ketoconazol ( 400 mg / day ), a metabolism inhibitor and a P-gP dependent transport system.
• Excessive peripheral dopamine signaling causes many of the adverse Stalevo ( Orion Corporation ) or with a benserazide ( combination medicines are branded Madopar or Prolopa ), to prevent the peripheral synthesis of dopamine from L-DOPA . Coadministration of pyridoxine without a DDCI accelerates the peripheral decarboxylation of L-DOPA to such an extent that it negates the effects of L-DOPA administration, a phenomenon that historically caused great confusion.